-
Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia
The first FA patients ever have been injected with Frataxin (protein replacement therapy, phase 1 safety trial). The lack of Frataxin is the root problem, and here we are in the age that the protein we need has made it to a syringe for human safety trials. That’s next level exciting!
According to the press release, we should hear the safety data results by the end of 2020. I hope it’s well-tolerated and we can move into phase 2 (efficacy trials) quickly!’
How do you feel about these recent news? For me I feel extra hopeful and thankful there are people of there who want a treatment and/or cure just as much!
-
1 Reply
-
This is the first treatment I feel deals with replacing frataxin levels. I’m very excited and honestly hopeful for the first time that a real cure is coming.
Fingers crossed that it works quickly and effectively, and it can be available to all in need soon.
Log in to reply.